Biotech Showcase™ Provides Private and Micro- to Mid-Cap Public Company Executives One-Stop Access to Investors, Pharma ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

Hennion & Walsh CIO Kevin Mahn explains Morning Brief host Julie Hyman some of his investing outlooks for 2026, as he tries to "follow the money" on certain biotech and pharmaceutical trends. Also ...

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to ...

Biotech companies that will lead the next decade wont just have better science, theyll have superior operating models, writes ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

aTyr Pharma's leading candidate is targeting a relatively large market with unmet needs. The biotech company is expected to release data from a phase 3 clinical trial soon. Though things look somewhat ...

Speculative investors and patience rarely go hand in hand. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is a requirement. Most, if not all, of these companies ...

Biotech stocks have staged an impressive rally over the past six months, with the XBI index – key benchmark for small and mid ...

Pulmonary sarcoidosis patients could soon get the treatment option they've been waiting for from aTyr Pharma. MoonLake Immunotherapeutics is running multiple phase 3 programs for its lead candidate.

Some prominent biotech companies tend to capture the majority of investors' and analysts' attention compared to their industry peers. aTyr Pharma (NASDAQ: LIFE), a small-cap, clinical-stage biotech, ...